tbuckley/cabot-search huggingface dataset:
Herpes Simplex Virus Encephalitis: Therapy Trials
Authors: A. MARTIN LERNER
Journal: Annals of Internal Medicine (1973)

Comments and Corrections1 August 1973Herpes Simplex Virus Encephalitis: Therapy TrialsA. MARTIN LERNER, M.D., CARL B. LAUTER, M.D., DAVID C. NOLAN, M.D.A. MARTIN LERNER, M.D.Search for more papers by this author, CARL B. LAUTER, M.D.Search for more papers by this author, DAVID C. NOLAN, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-79-2-285_2 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the editor: We would like to remark on the comment to the Editor in the May issue (Ann Intern Med78:779, 1973), by Hirsch, Levin, and Chien, related to our recent article (Ann Intern Med78:243-246, 1973) concerning experience with idoxuridine in 29 cases of herpes simplex virus encephalitis studied by us from 1966 to 1971. We quote from the letter of Hirsch and colleagues: "little appears to be gained by further publication of uncontrolled studies or case reports of various modes of therapy in this disorder." Hirsch properly indicates that "two controlled randomized multicenter studies on the role... This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Hutzel Hospital Medical Unit Department of Medicine Wayne State University School of Medicine Detroit, Michigan PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 August 1973Volume 79, Issue 2Page: 285-285KeywordsEncephalitisHerpes simplex Issue Published: 1 August 1973 PDF downloadLoading ...
Experience in Monitoring Gentamicin Therapy during Treatment of Serious Gram-Negative Sepsis
Authors: P. Noone, T. M. C. Parsons, J. R. Pattison, R. C. B. Slack, D. Garfield-Davies, K. Hughes
Journal: BMJ (1974)

This paper reports our experience in monitoring gentamicin therapy during the treatment of 68 episodes of serious Gram-negative sepsis in 65 hospital patients. Most of the patients had major underlying disease. Of those who were adequately treated (peak serum concentrations of 5 mug/ml or more in 72 hours for septicaemia, urinary tract infection, and wound infection; and 8 mug/ml or more at some time during the course of treatment for pneumonia) 84% (46 out of 55) were cured. These serum concentrations could be achieved only by starting with a regimen of 5 mg/kg/day in three divided doses in all adult patients, subsequent dosage being determined by the results of rapid serum assay. The incidence of nephrotoxicity and symptomatic ototoxicity was no greater than in previous series. The main reason for assaying serum gentamicin is to ensure that an adequate dosage is achieved as soon as possible. In patients with impaired renal function or receiving prolonged high dosage assays also serve to guard against an excessive accumulation of gentamicin and an increased risk of toxicity.
Hepatitis C Virus Core Protein Inhibits Tumor Suppressor Protein Promyelocytic Leukemia Function in Human Hepatoma Cells
Authors: Kerstin Herzer, Sandra Weyer, Peter H. Krammer, Peter R. Galle, Thomas G. Hofmann
Journal: Cancer Research (2005)

Abstract Tumor suppressor protein promyelocytic leukemia (PML) is implicated in apoptosis regulation and antiviral response. PML localizes predominantly to PML-nuclear bodies (PML-NB), nuclear macromolecular complexes regulating tumor suppressor protein p53 activity. Consistent with the function of PML in the cellular antiviral response, PML-NBs represent preferential targets in viral infections. In the case of hepatitis C virus (HCV) infection, important characteristics are nonresponsiveness to IFN therapy and development of hepatocellular carcinoma. However, the mechanisms which lead to the development of hepatocellular carcinoma are largely unknown. Here, we show that HCV core protein localizes to the cell nucleus in PML-NBs, where it colocalizes with p53. The HCV core interacts with endogenously expressed PML isoform IV (PML-IV), a key regulator of p53 activity. Importantly, we show that HCV core protein inhibits PML-IV–induced apoptosis and interferes with the coactivator function of PML-IV for proapoptotic p53 target genes including CD95 (Fas/APO-1). In particular, we found that the HCV core inhibits p53-mediated target gene expression by predominantly targeting the coactivator function of PML-IV because HCV core–mediated p53 target gene repression was absent in PML-ablated cells. HCV core expression abrogated both p53 serine 15 phosphorylation and lysine 382 acetylation, two p53-activating posttranslational modifications which were previously linked to an increased PML-NB formation. Taken together, our results suggest a potential mechanism for HCV-associated development of hepatocellular carcinoma through HCV core–mediated inactivation of the PML tumor suppressor pathway.
Ear involvement in acute promyelocytic leukemia at relapse: a disease-associated ‘sanctuary’?
Authors: M Breccia, MC Petti, AM Testi, G Specchia, F Ferrara, D Diverio, A Romano, V Guerrisi, A Greco, ML Fiorella, M de Vincentiis, F Mandelli, F Lo Coco
Journal: Leukemia (2002)
EFFECTS OF HEPARIN ON THE LIPOPROTEINS IN HYPERLIPEMIA. AN ELECTROPHORETIC STUDY OF THE SERUM ALPHA AND BETA LIPOPROTEINS AFTER THEIR SEPARATION BY FRACTIONATION OF THE PLASMA PROTEINS OR ULTRACENTRIFUGAL FLOTATION 1
Authors: Franz S. M. Herbst, Walter F. Lever, Mary E. Lyons, Nancy A. Hurley
Journal: Journal of Clinical Investigation (1955)
NT-proBNP levels at spontaneous breathing trial help in the prediction of post-extubation respiratory distress
Authors: Lamia Ouanes-Besbes, Fahmi Dachraoui, Islem Ouanes, Rania Bouneb, Faten Jalloul, Mohamed Dlala, Mohamed Fadhel Najjar, Fekri Abroug
Journal: Intensive Care Medicine (2012)
&lt;emph type="ital"&gt;Breakfast With a Lobster&lt;/emph&gt;
Authors: M. Therese Southgate
Journal: JAMA (2008)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Observations of cancer incidence surveillance in Duluth, Minnesota.
Authors: E E Sigurdson
Journal: Environmental Health Perspectives (1983)

In 1973, amphibole asbestos fibers were discovered in the municipal water supply of Duluth, Minnesota. The entire city population of approximately 100,000 was exposed from the late 1950s through 1976 at levels of 1-65 million fibers per liter of water. Because of previous epidemiologic studies that linked mesothelioma, lung and gastrointestinal cancers to occupational exposure to asbestos, surveillance of cancer incidence in residents of Duluth was initiated to determine the health effect from ingestion of asbestos. The methodology of the Third National Cancer Survey (TNCS) and SEER Program was used. Duluth 1969-1971 rates were compared with TNCS rates for the cities of Minneapolis and St. Paul during 1969-1971; Duluth rates during 1974-1976 are compared with Duluth 1969-1971; Duluth rates during 1979-1980 are compared with Duluth 1969-1971 and with Iowa SEER; and a table of the occurrence of malignant mesothelioma is presented. Statistically significant excesses are observed in several primary sites in Duluth residents. However, lung cancer in Duluth females is the only primary site considered also of biological significance. The mesothelioma incidence rate is no more than expected. This paper also describes the problems of long-term surveillance of exposed populations considered at risk of environment cancer, the need for improved study methodologies and the use of federal records for follow up of exposed individuals.
CHARACTERISTICS OF PATIENTS REHOSPITALIZED WITH ACUTE DECOMPENSATED HEART FAILURE (ADHF) WITHIN 30 DAYS FOLLOWING DISCHARGE
Authors: Sandip K. Zalawadiya, Hammam D. Zmily, Jareer O. Farah, Suleiman Daifallah, Omaima A. Ali, Jalal K. Ghali
Journal: Journal of the American College of Cardiology (2010)
The natural history of liver regeneration in rats: Description of an animal model for liver regeneration studies
Authors: Kasper Jarlhelt Andersen, Anders Riegels Knudsen, Anne-Sofie Kannerup, Hideki Sasanuma, Jens Randel Nyengaard, Stephen Hamilton-Dutoit, Erland J. Erlandsen, Bo Jørgensen, Frank Viborg Mortensen
Journal: International Journal of Surgery (2013)
Abstract 4227: Simple identification of specific mutations using allele-specific PCR primers and micro capillary electrophoresis (WAVE MCE).
Authors: Katherine A. Richardson, Grant Wu, Rui Lin, Yanggu Shi, Phil Eastlake, Benjamin Legendre
Journal: Cancer Research (2013)

Abstract Transgenomic, Inc. has developed a size-based analysis for the detection of all EGFR Exon 19 deletions (including complex mutation) greater than 6 base pairs (ACE™ Kit EGFR Exon 19). Currently there are over 70 known EGFR Exon 19 deletions in the region important for response of non-small cell lung cancer (NSCLC) to thymidine kinase inhibitors (TKIs). The majority of these deletions are rare, but the patients may benefit from TKI treatment if the deletion is present. In most current testing paradigms, a NSCLC patient with one of these rare mutations would be considered EGFR mutation negative and not receive TKI therapy. We have designed an easy, size-based PCR assay to detect any of the deletions present in any sample after a single PCR reaction. The assay is based on the separation of PCR fragments of different sizes using microcapillary electrophyoresis (MCE). Transgenomic's WAVE® MCE platform can discriminate the deletions from the wild-type sequence in EGFR Exon 19, however the exact nature of the mutation cannot be determined. If the exact nature of the mutation is required, the PCR fragment can be sequenced. To confirm that the platform can detect common and rare mutations, plasmids containing various EGFR Exon 19 deletions were synthesized, mixed with EGFR wild-type plasmids and analyzed on the WAVE® MCE platform. The Limit of detection for the plasmid mixing experiments is between 0.5 and 1% for all plasmid constructs tested. These plasmids include 6, 9, 15, 21, 24, and 25 bp deletions . As all samples tested have some wild-type sequence present, 6 base pair deletions cannot be resolved from the wild-type fragment. Several of the deletion constructs contain those not detected by any allele-specific kit, however patients with these deletions, as determined by Sanger sequence analysis, have benefitted from TKI therapy. In addition cell line DNA and DNA isolated from FFPE sections have been analyzed for the detection of EGFR Exon 19 deletions and similar limits of detection (0.5-1.0%) were seen. This simple, size-based analysis for EGFR Exon deletions will result in NSCLC patients with both common and rare EGFR Exon 19 deletions being able to receive the treatment option best suited for their molecular profile. Citation Format: Katherine A. Richardson, Grant Wu, Rui Lin, Yanggu Shi, Phil Eastlake, Benjamin Legendre. Simple identification of specific mutations using allele-specific PCR primers and micro capillary electrophoresis (WAVE MCE). [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 4227. doi:10.1158/1538-7445.AM2013-4227
AB0811-PC Efficacy and safety of certolizumab pegol with methotrexate in rheumatoid arthritis patients
Authors: G. Carlino, A. Cozzolongo, R. Maggio
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Certolizumab Pegol (CZP), administered every 2 weeks in combination with Methotrexate (MTX), showed rapid efficacy and had an acceptable safety profile in patients(pts) with RA in several clinical trials. <h3>Objectives</h3> To confirm the efficacy and safety of CZP+MTX in pts with active RA and an previous inadequate response to MTX. <h3>Methods</h3> In this study 17 pts [mean age±DS:50±7.1 years (min-max 38-62)] with active RA [CRP: 11.1±5.7 mg/L (6.3-24), ESR: 38.9±12.6 (24-67) mm/h, DAS28(ESR): 4.7±0.4 (4.1-5.2), HAQ: 1.9±0.3 (1,0-2.3)] received CZP every two weeks (Wks) [a dose of 400mg for the first three times (at Wks 0, 2 and 4) followed by 200mg] and a stable dose of MTX (10-20 mg/Wk) for 52 weeks. <h3>Results</h3> 16 pts completed the study, because a case of pancytopenia determined the discontinuation of the drug in one pt. This was the only adverse event. DAS28(ESR) was significantly lower after 52 Wks (P=0.00013). HAQ, pain and global disease activity had significantly improved after 52 Wks. In table I is shown the average value of DAS28(ESR), ESR, CRP and HAQ at the beginning of the study (T0) and after 52 Weeks (T52). <h3>Image/graph</h3> <h3>Conclusions</h3> Use of CZP 200mg (after three initial subministrations of 400 mg) every 2 Wks + MTX resulted in a rapid and sustained reduction of RA signs, symptoms and pain, and improved physical function. CZP had an acceptable safety profile. This confirms the efficacy and safety of CZP in MTX refractary RA. <h3>Disclosure of Interest</h3> None Declared
Endogenous Sex Hormones and Type 2 Diabetes Risk
Authors: Carolyn A. Bondy
Journal: JAMA (2006)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Relation of pediatric blood lead levels to lead in gasoline.
Authors: I H Billick, A S Curran, D R Shier
Journal: Environmental Health Perspectives (1980)

Analysis of a large data set of pediatric blood lead levels collected in New York City (1970-1976) shows a highly significant association between geometric mean blood lead levels and the amount of lead present in gasoline sold during the same period. This association was observed for all age and ethnic groups studied, and it suggests that possible exposure pathways other than ambient air should be considered. Even without detailed knowledge of the exact exposure pathways, sufficient information now exists for policy analysis and decisions relevant to controls and standards related to lead in gasoline and its effect on subsets of the population.
Japanese Language Barrier to Communication
Authors: Lester C. Mark
Journal: JAMA (1969)

<h3>To the Editor: —</h3> An item titled "Promising Results Obtained With New Cardiac Valve," in the MEDICAL NEWS section (<b>205</b>: Sept 16, 1968, adv p 34) describes an artificial heart valve developed by Drs. W. S. Pierce, D. M. Behrendt, and Andrew G. Morrow at the National Heart Institute, Bethesda, Md. The valve is described and pictured as a stainless steel disk pivoting to an opening of up to 75 degrees on an eccentric hinge set in an annular valve body, the whole resembling a "butterfly valve" in an automobile carburetor. This design, while ingenious, is not unique: Priority of invention must be assigned to Juro Wada, MD, professor of surgery and chairman of the Department of Thoracic and Cardiovascular Surgery at Sapporo Medical College and Hospital ("Idai") in Japan. I was privileged to see the Wada "hingeless hinge" valve at first hand last year at Idai in the Department
Problem Solving in Clinical Medicine: From Data to Diagnosis
Authors: Stanford Wessler
Journal: JAMA (1985)

This volume is specifically designed for the medical student who is at or just beyond the junction of preclinical and clinical experiences. There are 31 contributing physicians, 25 of whom are at the University of Texas Health Science Centers at San Antonio. The book is written and guided by an obviously experienced senior physician, whose goal is to enable students "to enter the physician's mind during the gathering of data and to learn why he pursues certain pathways in his quest for solutions." The volume is obviously more than that, but, to this reviewer, that is its most notable message. The first half is effectively conceptual and methodological, reminding medical students that they can, in fact, utilize their broad knowledge in the care of actual patients. The second half provides specific examples of "problem solving in action." Students might enjoy looking at specific case studies in this section to determine
Ventricular Ectopy
Authors: Michael J. Horan
Journal: JAMA (1984)

IS VENTRICULAR ectopy always a manifestation of a disease process or can it be found in normal persons? When present, should ventricular ectopy always be treated? To answer these questions, one must delve into medical history, a history rich in anecdote and opinion but muddled in its distinction between disease and health. We review herein the historical development of knowledge about, and attitudes toward, ventricular ectopy, the recent reports delineating patients with ventricular ectopy into prognostically different subsets, and the current approach to the treatment of patients with ventricular ectopy. <h3>Historical Perspective</h3> Although the art of palpating the pulse was practiced as early as 500 BC in ancient China,<sup>1</sup>it was not until the second century BC that Herophilus described what we now recognize as extrasystoles.<sup>2</sup>However, writers after Herophilus did not make reference to extrasystoles per se but rather talked about the "intermittent pulse." The most influential
Charity commits more money to investigating cancers with poor survival
Authors: S. Mayor
Journal: BMJ (2008)

Cancer Research UK, a major independent funder of research into cancer, will focus on cancers that have poor survival rates, including pancreatic, oesophageal, and lung cancers, it says in its five year plan published today. It will also increase investment in research into radiotherapy and surgical techniques.

The plan sets out the details of how the organisation will spend its budget of around £300m (€360m; $460m) a year to reduce cancer mortality. Although the charity will remain the United Kingdom’s largest funder of research into a range of cancers, it will introduce major initiatives in research into pancreatic and oesophageal cancers and increase funding for research into lung cancer, with special funding streams for work in these areas.

Harpal Kumar, the charity’s chief executive, said, “In these three cancers there has been a degree of nihilism …
Physical capacity and dyspnea in patients with asthma‐like symptoms but negative asthma tests
Authors: K. C. Ringsberg, H. Wetterqvist, O. Löwhagen, T. Sivik
Journal: Allergy (1997)

Ringsberg KC, Wetterqvist H, Löwhagen O, Sivik T. Physical capacity and dyspnea in patients with asthma‐like symptoms but negative asthma tests. Ten female patients with asthma‐like symptoms but negative asthma tests ‘study group’ were compared with 10 female asthmatics in an exercise test with and without pretreatment with β 2 ‐stimulants. The aim was to determine whether the asthma‐like symptoms in the patients of the study group could be explained by bronchoconstriction, circulatory abnormalities, or physical unfitness when provoked physically, and whether the exercise test could be used to distinguish these patients from asthmatics. Without pretreatment, the asthma group reacted with bronchoconstriction, as indicated by postexercise systematic changes in PEFR, FEV 1 , FVC, and S a o 2 , which were not seen in the study group. The groups differed in the ratings of “difficulty in getting air”, as only the asthma group had significantly lower ratings when pretreated. The study group's mean test performance was 94 W; the asthma group's was 106 W. The low performance was not explained by disturbances in heart rate, electrocardiogram, or blood pressure or physical unfitness. The exercise test was found to distinguish between the groups, especially for bronchoconstriction, oxygen saturation, and ratings of dyspnea. It could be used complementary to lung function tests to eliminate bronchoconstriction, circulatory abnormalities, and physical unfitness as a cause of the asthma‐like symptoms.
Hypermagnesemia Following Irrigation of Renal Pelvis
Authors: Donald B. Jenny
Journal: JAMA (1978)

HYPERMAGNESEMIA is most commonly associated with renal insufficiency or an exogenous source of magnesium.<sup>1</sup>Although magnesium-containing antacids and cathartics constitute the most common source of exogenous magnesium,<sup>2</sup>urologic irrigation solutions, used for the dissolution of urinary calculi, may also contain magnesium.<sup>3</sup>While modest elevations in serum magnesium have been described with the use of such irrigation solutions,<sup>4</sup>elevations of this ion sufficient to cause respiratory paralysis have, to our knowledge, not been previously reported. We treated such a patient. <h3>Report of a Case</h3> A 35-year-old man, paraplegic as a result of a thoracolumbar menigomyelocele, was admitted to St Joseph Hospital on Aug 3, 1977, for evaluation of fever and foul-smelling urine of 24 hours' duration. The patient had a chronic suprapubic catheter and in the past had had numerous episodes of urinary tract infections associated with right renal calculi and mild chronic renal insufficiency. There was no